STOCKHOLM, SWEDEN / ACCESSWIRE / December 29, 2023 / iZafe Group (STO:IZAFE-B) iZafe Group AB ("iZafe Group") announces today that they have received an official order for 1,000 units of Dosell in accordance with the agreement announced on February 27, 2023. These units will be produced as soon as possible and are expected to be delivered to IVE Ventures ("IVE") in February 2024.
Earlier this year, iZafe announced an exclusive partnership with IVE, giving them the sole rights to sell and market Dosell medication robots in the Netherlands. According to this agreement, IVE committed to purchasing a minimum of 1,000 Dosell units each year for a three-year period to retain exclusivity. The total value of hardware purchases and license revenues over the first three years amounts to approximately 16 million SEK, with annual recurring license revenues of at least 6 million SEK thereafter.
"We look forward to continuing our partnership with iZafe Group and introducing Dosell to the Dutch market. This order for 1,000 units is a clear demonstration of our dedication to promoting innovative health and healthcare solutions," says Martijn Van Bree, CEO of IVE Ventures.
IVE's commitment to improving health and healthcare solutions and their dedication to Dosell is evident through their initial order of 1,000 Dosell units. Their promise to annually purchase at least 1,000 units to maintain exclusivity in the Dutch market reflects their strategic approach to strengthening their portfolio. With extensive experience in providing connected health and healthcare services since 2014, IVE has identified Dosell's potential to enhance and provide a reliable and secure medication solution to their customers in healthcare and alarm services in the Netherlands.
Contacts
Anders Segerström, Chief Executive Officer
E-mail: [email protected]
Phone number: +46 70-875 14 12
iZafe Group AB (publ.)
David Bagares gata 3
111 38 Stockholm
E-mail: [email protected]
www.izafegroup.com
eucaps.com/izafe-group
About iZafe Group AB (publ.)
iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.
The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution Pilloxa with the smart pillbox. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.
The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.
iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com
Image Attachments
Självständig Medicinering Hemtjänst
Attachments
iZafe Group receives confirmed order for 1,000 Dosell units to the Netherlands
SOURCE: iZafe Group